Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Date:10/4/2011

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Gu
'/>"/>

SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... October 6, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... tiaras to anklets are treasures but these gemstones inside ... Reserve University researchers are building implants made of diamond ... and electrical changes in the brain of patients suffering ... movement in the paralyzed. The work of Heidi ...
... Oct. 4 issue of the high-impact journal, Applied ... the University of Cincinnati and start-up company Gamma Dynamics ... electronic devices. This patent-pending electrofluidics breakthrough by the ... partner companies Gamma Dynamics, Dupont and Sun Chemical follows ...
Cached Biology Technology:Elsevier Introduces Article-Based Publishing to Increase Publication Speed 2Elsevier Introduces Article-Based Publishing to Increase Publication Speed 3Elsevier Introduces Article-Based Publishing to Increase Publication Speed 4Elsevier Introduces Article-Based Publishing to Increase Publication Speed 5Elsevier Introduces Article-Based Publishing to Increase Publication Speed 6Elsevier Introduces Article-Based Publishing to Increase Publication Speed 7Elsevier Introduces Article-Based Publishing to Increase Publication Speed 8Gem of an idea: A flexible diamond-studded electrode implanted for life 2Gem of an idea: A flexible diamond-studded electrode implanted for life 3Breakthrough e-display means electronics with high speed, high readability and low power usage 2Breakthrough e-display means electronics with high speed, high readability and low power usage 3Breakthrough e-display means electronics with high speed, high readability and low power usage 4
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/31/2014)... 2014  HITLAB SM , a healthcare innovation ... inaugural HITLAB Innovators Summit SM on December ... will partner with the Clinton Foundation,s Health Matters ... Columbia Business School Alumni Club of ... and Operations Research, bringing together leaders in healthcare ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Identifying the source of stem cells 2
... from brake linings and mining operations can affect salmon ... a Washington State University researcher. Jenifer McIntyre found the ... they won,t detect a compound that ordinarily alerts them ... is not getting the information it needs to make ...
... Switzerland. Research to be presented at the Annual Meeting of ... foremost society for research into all aspects of eating and ... reduces the quality of sleep in rats. Using radio-telemetry, ... consumed a high fat diet for 8 weeks. Compared to ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Copper making salmon prone to predators 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: